Insulet Corporation (PODD) Financial Ratios
22 years of historical data (2004–2025) · Healthcare · Medical - Devices
EV/EBITDA
↓
19.76
↓-78% vs avg
5yr avg: 91.55
30Y Low35.4·High57.3
P/FCF
↓
29.81
↓-74% vs avg
5yr avg: 115.06
30Y Low54.1·High63.2
P/B Ratio
↓
7.61
↓-70% vs avg
5yr avg: 25.44
30Y Low4.2·High140.5
ROE
↑
18.1%
-9% vs avg
5yr avg: 19.8%
30Y Low-278%·High43%
Debt/EBITDA
↓
1.79
↓-72% vs avg
5yr avg: 6.32
30Y Low1.8·High14.2
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
PODD Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Insulet Corporation trades at 46.1x earnings, 96% below its 5-year average of 1147.8x, sitting at the 33rd percentile of its historical range. Compared to the Healthcare sector median P/E of 22.3x, the stock trades at a premium of 106%. On a free-cash-flow basis, the stock trades at 29.8x P/FCF, 74% below the 5-year average of 115.1x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $11.3B | $20.4B | $19.3B | $16.0B | $20.6B | $18.2B | $16.9B | $10.7B | $4.8B | $4.0B | $2.2B |
| Enterprise Value | $11.6B | $20.8B | $19.8B | $16.8B | $21.4B | $18.7B | $17.0B | $11.4B | $5.3B | $4.3B | $2.4B |
| P/E Ratio → | 46.09 | 81.68 | 45.17 | 73.80 | 4474.01 | 1064.28 | 2556.30 | 901.05 | 1468.89 | — | — |
| P/S Ratio | 4.16 | 7.55 | 9.31 | 9.41 | 15.77 | 16.61 | 18.64 | 14.45 | 8.58 | 8.63 | 5.88 |
| P/B Ratio | 7.61 | 13.49 | 15.92 | 21.81 | 43.20 | 32.80 | 27.93 | 140.53 | 22.82 | 25.25 | 34.16 |
| P/FCF | 29.81 | 54.10 | 63.16 | 227.92 | — | — | — | — | — | — | — |
| P/OCF | 19.78 | 35.89 | 44.83 | 109.66 | 172.95 | — | 200.69 | 108.40 | 134.80 | 96.91 | 135.58 |
P/E links to full P/E history page with 30-year chart
PODD EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
Insulet Corporation's enterprise value stands at 19.8x EBITDA, 78% below its 5-year average of 91.6x. The Healthcare sector median is 14.4x, placing the stock at a 37% premium on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 7.67 | 9.54 | 9.88 | 16.39 | 17.06 | 18.83 | 15.40 | 9.43 | 9.26 | 6.41 |
| EV / EBITDA | 19.76 | 35.39 | 50.70 | 57.29 | 212.20 | 102.19 | 159.28 | 145.94 | 123.66 | 660.90 | 752.03 |
| EV / EBIT | 24.47 | 43.83 | 57.62 | 66.89 | 467.02 | 228.00 | 310.14 | 245.54 | 168.80 | — | — |
| EV / FCF | — | 54.98 | 64.70 | 239.30 | — | — | — | — | — | — | — |
PODD Profitability
Margins and return-on-capital ratios measuring operating efficiency
Insulet Corporation earns an operating margin of 17.5%. Operating margins have expanded from 13.0% to 17.5% over the past 3 years, signaling improving operational efficiency. ROE of 18.1% indicates solid capital efficiency. ROIC of 20.1% represents excellent returns on invested capital.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 71.6% | 71.6% | 69.8% | 68.3% | 61.7% | 68.4% | 64.4% | 65.1% | 65.7% | 59.8% | 57.5% |
| Operating Margin | 17.5% | 17.5% | 14.9% | 13.0% | 2.9% | 11.5% | 5.7% | 6.8% | 4.9% | -1.6% | -2.9% |
| Net Profit Margin | 9.1% | 9.1% | 20.2% | 12.2% | 0.4% | 1.5% | 0.8% | 1.6% | 0.6% | -5.8% | -7.9% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 18.1% | 18.1% | 43.0% | 34.1% | 0.9% | 2.9% | 2.0% | 8.1% | 1.8% | -24.2% | -59.4% |
| ROA | 7.9% | 7.9% | 14.7% | 8.5% | 0.2% | 0.9% | 0.5% | 1.1% | 0.4% | -4.2% | -7.9% |
| ROIC | 20.1% | 20.1% | 14.4% | 11.7% | 2.4% | 10.4% | 5.0% | 5.1% | 3.6% | -1.6% | -4.6% |
| ROCE | 18.7% | 18.7% | 13.2% | 10.9% | 2.0% | 7.2% | 3.9% | 5.6% | 3.5% | -1.3% | -3.5% |
PODD Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Insulet Corporation carries a Debt/EBITDA ratio of 1.8x, which is manageable (46% below the sector average of 3.3x). Net debt stands at $335M ($1.1B total debt minus $716M cash). Interest coverage of 5.9x is adequate, though a cyclical earnings downturn could tighten the margin of safety.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.69 | 0.69 | 1.17 | 1.98 | 3.01 | 2.31 | 1.78 | 11.94 | 2.79 | 3.57 | 5.27 |
| Debt / EBITDA | 1.79 | 1.79 | 3.65 | 4.95 | 14.21 | 7.01 | 10.07 | 11.63 | 13.77 | 87.10 | 106.44 |
| Net Debt / Equity | — | 0.22 | 0.39 | 1.09 | 1.70 | 0.89 | 0.28 | 9.25 | 2.25 | 1.85 | 3.10 |
| Net Debt / EBITDA | 0.57 | 0.57 | 1.20 | 2.73 | 8.02 | 2.70 | 1.58 | 9.01 | 11.12 | 45.17 | 62.60 |
| Debt / FCF | — | 0.89 | 1.53 | 11.39 | — | — | — | — | — | — | — |
| Interest Coverage | 5.94 | 5.94 | 8.03 | 6.93 | 1.27 | 1.33 | 1.14 | 1.34 | 1.42 | -0.39 | -0.86 |
PODD Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Insulet Corporation's current ratio of 2.78x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The quick ratio of 2.11x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has declined from 3.47x to 2.78x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.78 | 2.78 | 3.54 | 3.47 | 3.56 | 5.75 | 5.96 | 3.69 | 3.93 | 6.24 | 6.64 |
| Quick Ratio | 2.11 | 2.11 | 2.73 | 2.58 | 2.61 | 4.43 | 5.21 | 3.05 | 3.31 | 5.85 | 6.00 |
| Cash Ratio | 1.05 | 1.05 | 1.80 | 1.56 | 1.85 | 3.46 | 4.56 | 2.38 | 2.50 | 5.12 | 5.36 |
| Asset Turnover | — | 0.85 | 0.67 | 0.66 | 0.58 | 0.54 | 0.48 | 0.65 | 0.61 | 0.57 | 0.80 |
| Inventory Turnover | 1.70 | 1.70 | 1.45 | 1.33 | 1.44 | 1.14 | 2.09 | 2.55 | 2.71 | 5.52 | 4.39 |
| Days Sales Outstanding | — | 69.67 | 64.40 | 77.36 | 57.49 | 53.48 | 33.82 | 40.94 | 49.63 | 42.01 | 28.65 |
PODD Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Insulet Corporation returns 0.5% to shareholders annually primarily through share buybacks. The earnings yield of 2.2% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 2.2% | 1.2% | 2.2% | 1.4% | 0.0% | 0.1% | 0.0% | 0.1% | 0.1% | — | — |
| FCF Yield | 3.4% | 1.8% | 1.6% | 0.4% | — | — | — | — | — | — | — |
| Buyback Yield | 0.5% | 0.3% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.5% | 0.3% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $72M | $74M | $74M | $70M | $69M | $66M | $62M | $61M | $58M | $57M |
Peer Comparison
Compare PODD with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 PODDYou | $11B | 46.1 | 19.8 | 29.8 | 71.6% | 17.5% | 18.1% | 20.1% | 1.8 |
 DXCM | $24B | 29.1 | 20.6 | 21.8 | 60.0% | 19.6% | 34.5% | 18.7% | 1.2 |
 TNDM | $1B | -6.1 | — | — | 52.3% | -7.7% | -97.9% | -10.0% | — |
 NVCR | $2B | -13.8 | — | — | 74.5% | -23.5% | -38.9% | -16.4% | — |
 ITGR | $3B | 30.4 | 13.1 | 28.8 | 23.1% | 11.3% | 6.1% | 5.4% | 4.2 |
 ABT | $151B | 11.4 | 15.8 | 23.8 | 50.8% | 16.3% | 30.9% | 9.9% | 1.5 |
 MDT | $100B | 21.6 | 14.3 | 19.3 | 65.3% | 17.8% | 9.4% | 6.0% | 3.2 |
 BDX | $56B | 26.3 | 14.7 | 20.8 | 45.4% | 11.8% | 6.5% | 4.3% | 3.8 |
 NVO | $203B | 12.6 | 9.3 | 44.6 | 81.0% | 41.3% | 60.7% | 36.2% | 0.9 |
 LLY | $921B | 42.5 | 30.6 | 102.7 | 83.8% | 45.6% | 101.2% | 41.8% | 1.4 |
 SNY | $104B | 18.1 | 10.8 | 10.0 | 72.3% | 13.6% | 10.4% | 5.5% | 2.3 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 22 years · Updated daily
Full PODD Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See PODD's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs PODD Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare PODD vs DXCM
Side-by-side business, growth, and profitability comparison vs DexCom, Inc..
Start ComparisonPODD — Frequently Asked Questions
Quick answers to the most common questions about buying PODD stock.
What is Insulet Corporation's P/E ratio?
Insulet Corporation's current P/E ratio is 46.1x. The historical average is 66.9x. This places it at the 33th percentile of its historical range.
What is Insulet Corporation's EV/EBITDA?
Insulet Corporation's current EV/EBITDA is 19.8x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 47.8x.
What is Insulet Corporation's ROE?
Insulet Corporation's return on equity (ROE) is 18.1%. The historical average is -52.9%.
Is PODD stock overvalued?
Based on historical data, Insulet Corporation is trading at a P/E of 46.1x. This is at the 33th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Insulet Corporation's profit margins?
Insulet Corporation has 71.6% gross margin and 17.5% operating margin. Operating margin between 10-20% is typical for established companies.
How much debt does Insulet Corporation have?
Insulet Corporation's Debt/EBITDA ratio is 1.8x, indicating moderate leverage. A ratio below 2x is generally considered financially healthy.